首页> 美国卫生研究院文献>AIDS Research and Treatment >Determinants of Mortality among Adult HIV-Infected Patients on Antiretroviral Therapy in a Rural Hospital in Southeastern Nigeria: A 5-Year Cohort Study
【2h】

Determinants of Mortality among Adult HIV-Infected Patients on Antiretroviral Therapy in a Rural Hospital in Southeastern Nigeria: A 5-Year Cohort Study

机译:尼日利亚东南部农村医院中接受抗逆转录病毒疗法的成人HIV感染患者死亡率的决定因素:一项为期5年的队列研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background. Study examined the determinants of mortality among adult HIV patients in a rural, tertiary hospital in southeastern Nigeria, comparing mortality among various ART regimens. Methods. Retrospective cohort study of 1069 patients on ART between August 2008 and October 2013. Baseline CD4 counts, age, gender, and ART regimen were considered in this study. Kaplan-Meier method was used to estimate survival and Cox proportional hazards models to identify multivariate predictors of mortality. Median follow-up period was 24 months (IQR 6–45). Results. 78 (7.3%) patients died with 15.6% lost to followup. Significant independent predictors of mortality include age (>45), sex (male > female), baseline CD4 stage (<200), and ART combination. Adjusted mortality hazard was 3 times higher among patients with CD4 count <200 cells/μL than those with counts >500 (95% CI 1.69–13.59). Patients on Truvada-based first-line regimens were 88% more likely to die than those on Combivir-based first line (95% CI 1.05–3.36), especially those with CD4 count <200 cells/μL. Conclusion. Study showed lower mortality than most studies in Nigeria and Africa, with mortality higher among males and patients with CD4 count <200. Further studies are recommended to further compare treatment outcomes between Combivir- and Truvada-based regimens in resource-limited settings using clinical indicators.
机译:背景。研究调查了尼日利亚东南部农村三级医院的成人HIV患者死亡率的决定因素,比较了各种抗病毒治疗方案的死亡率。方法。在2008年8月至2013年10月之间对1069例接受ART治疗的患者进行了回顾性队列研究。本研究考虑了基线CD4计数,年龄,性别和ART方案。 Kaplan-Meier方法用于评估生存率和Cox比例风险模型,以识别死亡率的多元预测因子。中位随访期为24个月(IQR 6–45)。结果。 78例患者(7.3%)死亡,随访损失15.6%。死亡率的重要独立预测因子包括年龄(> 45),性别(男性→女性),基线CD4阶段(<200)和ART组合。 CD4计数<200µcells /μL的患者中,校正后的死亡危险比计数> 500的患者高3倍(95%CI 1.69–13.59)。基于Truvada的一线治疗方案的患者比基于Combivir的一线治疗方案的患者(95%CI 1.05–3.36)死亡的可能性高88%,尤其是那些CD4计数<200µcells /μL的患者。结论。研究表明,与尼日利亚和非洲的大多数研究相比,死亡率更低,男性和CD4计数<200的患者死亡率更高。建议进一步研究,以使用临床指标进一步比较在资源有限的情况下基于Combivir和Truvada的治疗方案的治疗效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号